Sign In
Buy GDRX
$2.57
-0.0900 (-3.38%)
At Close: Jun 22, 2026
Kuehn Law Encourages Investors of GoodRx Holdings, Inc. to Contact Law Firm
03:17pm, Thursday, 31'st Oct 2024
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached
GoodRx Announces New Affordability Programs for Menopause Hormone Therapies
09:00am, Wednesday, 23'rd Oct 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced the availability of new affordability programs for menopause hormo
GoodRx Announces Date for Third Quarter 2024 Earnings Release and Conference Call
05:41pm, Thursday, 10'th Oct 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release
GoodRx Holdings: Failing To Gain Much Traction
02:46pm, Tuesday, 08'th Oct 2024
Today, we are circling back on GoodRx Holdings, which offers a platform for comparing prescription drug prices. The company also enables their customers to benefit from negotiated prices through GoodR
ELV vs. GDRX: Which Stock Is the Better Value Option?
12:48pm, Tuesday, 08'th Oct 2024
Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and GoodRx Holdings, Inc. (GDRX). But which of these two stocks presents investors
GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)
09:00am, Thursday, 26'th Sep 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS Pharmaceuticals, Inc. (“ARS Pharmaceutical
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ:
GoodRX Subscription Revenue Down 8% but Active User Numbers Are Up
04:01pm, Thursday, 08'th Aug 2024
It was a mixed bag of growth and challenges for digital healthcare platform GoodRx during the second quarter. In reporting its second-quarter results Thursday (Aug. 8), GoodRx said monthly active user
GoodRx Holdings, Inc. (GDRX) Q2 2024 Earnings Call Transcript
01:07pm, Thursday, 08'th Aug 2024
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Scott Wagner - Interim Chief Execu
GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges
12:04pm, Thursday, 08'th Aug 2024
Prescription savings platform GoodRx Holdings Inc. GDRX reported second-quarter revenue of $200.61 million, up 6% year over year, almost in line with the consensus of $200.4 million.
GoodRx (GDRX) Reports Q2 Earnings: What Key Metrics Have to Say
10:35am, Thursday, 08'th Aug 2024
Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street es
GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue Estimates
08:20am, Thursday, 08'th Aug 2024
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
GoodRx Reports Second Quarter 2024 Results
06:05am, Thursday, 08'th Aug 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released
Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates for Key Metrics
10:20am, Tuesday, 06'th Aug 2024
Besides Wall Street's top -and-bottom-line estimates for GoodRx (GDRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua
GoodRx Q2 Earnings Preview
03:44am, Wednesday, 31'st Jul 2024
GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance d
